Skip to main content

Table 2 Clinical characteristics of patients with BM.

From: Breast cancer subtypes and survival in patients with brain metastases

  No. (%) p Value*
  Total (n = 126) Luminal A (n = 23) Luminal B (n = 19) HER2+/ER- (n = 37) Triple-negative (n = 47)  
Age, mean (range), y 47 (22–70) 46 (34–65) 48 (29–70) 48 (28–69) 47 (22–69) 0.773
Age at BM       
≤ 45 years 59 (46.8) 13 (56.5) 8 (42.1) 16 (43.2) 22 (46.8) 0.746
> 45 years 67 (53.2) 10 (43.5) 11 (57.9) 21 (56.8) 25 (53.2)  
AJCC stage:       0.812
I 20 (15.9) 3 (13.0) 1 (5.3) 6 (16.2) 10 (21.3)  
II 34 (27.0) 6 (26.1) 7 (36.8) 8 (21.6) 13 (27.7)  
III 41 (32.5) 7 (30.4) 6 (31.6) 14 (37.8) 14 (29.8)  
IV 22 (17.5) 4 (17.4) 5 (26.3) 7 (18.9) 6 (12.8)  
Unknown 9 (7.1) 3 (13.0) 0 (0.0) 2 (5.4) 4 (8.5)  
Histology:       0.863
IDC 115 (91.3) 20 (87.0) 18 (94.7) 33 (89.0) 44 (93.6)  
ILC 6 (4.8) 1 (4.3) 1 (5.3) 2 (5.4) 2 (4.3)  
Mucinous 1 (0.8) 1 (4.3) 0 (0.0) 0 (0.0) 0 (0.0)  
Metaplatic 4 (3.2) 1 (4.3) 0 (0.0) 2(5.4) 1 (2.1)  
Disease-free interval, median (IQR), months 19.0 (25.0) 31.8(35.0) 26.9 (36.9) 17.5 (20.0) 17.0 (20.7) 0.1075
Interval from recurrence to BM, median (IQR), months 11.5 (15.2) 17.5 (36.0) 12.2 (17.0) 11.2 (14.3) 11.1 (14.5) 0.1473
Clinical features of BM:       0.053
Multiple 102 (81.0) 15 (65.2) 18 (94.7) 33 (89.2) 36 (76.6)  
Single 11 (8.7) 2 (8.7) 1 (5.3) 1 (2.7) 7 (14.9)  
LMD 13 (10.3) 6 (26.1) 0 (0.0) 3 (8.1) 4 (8.5)  
Number of disease sites:       0.834
< 3 42 (33.3) 9 (39.1) 5 (26.3) 13 (35.1) 15 (31.9)  
≥ 3 84 (67.7) 14 (60.9) 14 (73.7) 24 (64.9) 32 (68.1)  
Extracranical metastatic site:       
   Bone 80 (63.5) 18 (78.3) 16 (84.2) 24 (64.9) 22 (46.8) 0.010
   Lung/pleura 92 (73.0) 15 (65.2) 15 (78.9) 26 (70.3) 36 (76.6) 0.683
   Liver 52 (41.3) 10 (43.5) 13 (68.4) 14 (37.8) 15 (31.9) 0.053
   Skin/soft tissue/LN 94 (74.6) 15 (65.2) 12 (63.2) 30 (81.1) 37 (78.7) 0.122
  1. Abbreviations: AJCC, American Joint Committee on Cancer; BM, brain metastases; ER, estrogen receptor; HER2, human epidermal growth factor receptor-2; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; IQR, interquartile range; LMD; leptomeningeal disease; LN, lymph node.
  2. *Comparing four groups (luminal A, luminal B, HER2+, triple-negative) using analysis of variances to test for differences in means, Kruskall-Wallis test for difference in medians, and chi-square or Fisher's exact test for the remaining characteristics.